Parnassus Investments, an investment management company, released the “Parnassus Mid Cap Fund” third-quarter 2025 investor ...

PODD gains momentum as Omnipod 5 adoption accelerates, margins scale, and earnings estimates rise despite macro and concentration risks.

Fintel reports that on December 18, 2025, Truist Securities maintained coverage of Insulet (NasdaqGS:PODD) with a Buy recommendation. Analyst Price Forecast Suggests 31.68% Upside As of December 5, ...

Fintel reports that on November 19, 2025, UBS upgraded their outlook for Insulet (NasdaqGS:PODD) from Neutral to Buy. Analyst Price Forecast Suggests 9.42% Upside As of November 17, 2025, the average ...

(Photo by Kirk Mckoy/Los Angeles Times via Getty Images) When it comes to surgical innovation, Intuitive Surgical (NASDAQ: ISRG) often dominates investor attention. But Insulet Corporation (NASDAQ: ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Insulet Corporation is currently ...

The annual Boston conference will explore strategic partnering, device innovation, and delivery solutions for emerging therapeutics. The 15th annual Partnership Opportunities in Drug Delivery (PODD) ...

Insulin delivery company Insulet Corporation (NASDAQ:PODD) will be announcing earnings results tomorrow after market close. Here’s what to expect. Insulet beat analysts’ revenue expectations by 4.9% ...

The upcoming report from Insulet (PODD) is expected to reveal quarterly earnings of $0.77 per share, indicating an increase of 8.5% compared to the year-ago period. Analysts forecast revenues of ...

Insulet Corp.’s PODD recent FDA approval of Omnipod 5 for type 2 diabetes patients is set to expand the product’s market potential. The planned launch of Omnipod 5 with Abbott’s Freestyle Libre 2 Plus ...